Clinical Research of Live Cancer Treated by CEF Regimen Combined with Can Yi Capsule

Abstract

Objective: To explore the clinical effect ofCEF regimen combined with Can Yi capsule in the treatment of livercancer. Methods: From January 2014 to December 2020 our hospital received 118 patients withradical resection of liver cancery after radical surgery and they were divided into the observation group (n=59) and the control group (n=59). The observation group was treated withCEF regimen combined with Can Yi capsule, and the control group was treated withCEF alone. The short-term efficacy, NK and T lymphocyte subsets, quality of life and toxicity were compared between the observation group and the control group. Results: The ORR was 76.27%, and the DCR was 83.05% in the control group; the ORR was 91.53%, and the DCR was 96.61% in the experimental group, the difference was significant (P=0.024，P=0.015). After the intervention, the CD3+, CD4+, CD8+, CD4+/CD8+ and NK indexes in the experimental group were better than those in the control group ( P=0.000, P=0.000, P=0.000, P=0.000, P=0.000). In the physiological condition, psychological status, physical condition and sleep condition score, the experimental group was higher than the control group (P=0.012, P=0.014, P=0.009, P=0.013). In the joint pain, bone marrow suppression, arrhythmia, nausea and vomiting, alopecia, thrombocytopenia, leukopenia and anemia drug toxicity, the experimental group was lower than the control group (P＞0.05). Conclusion: For livercancer patients withradical resection of liver cancery, Can Yi capsule combined withCEF program could not only improve the short-term clinical efficacy, and improve immunity, but also could reduce drug toxicity and improve quality of life.